Expert Consensus on the Management of Adverse Events from EGFR Tyrosine Kinase Inhibitors in the UK-Reference-Cited by-同舟云学术

Expert Consensus on the Management of Adverse Events from EGFR Tyrosine Kinase Inhibitors in the UK

Published:2015-07-18 Issue:12 Volume:75 Page:1335-1348
ISSN:0012-6667
Container-title:Drugs
language:en
Short-container-title:Drugs

Author:

Califano R.,Tariq N.,Compton S.,Fitzgerald D. A.,Harwood C. A.,Lal R.,Lester J.,McPhelim J.,Mulatero C.,Subramanian S.,Thomas A.,Thatcher N.,Nicolson M.

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical)

Link

http://link.springer.com/article/10.1007/s40265-015-0434-6/fulltext.html

Reference46 articles.

1. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA. 2014;64(1):9–29.

2. Peters S, Adjei AA, Gridelli C, Reck M, Kerr K, Felip E, et al. Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann oncol. 2012;23(Suppl 7):vii56–64.

3. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 2004;350(21):2129–39.

4. Pao W, Miller V, Zakowski M, Doherty J, Politi K, Sarkaria I, et al. EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci. 2004;101(36):13306–11.

5. Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. 2004;304(5676):1497–500.

Cited by 98 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Antibacterial evaluation of 2-(6-Chloro-2-p-tolylquinazolin-4-ylthio) acetonitrile against pathogenic bacterial isolates with special reference to biofilm formation inhibition and anti-adherence properties;Journal of King Saud University - Science;2024-09

2. Nuclear Receptors and Stress Response Pathways Associated with the Development of Oral Mucositis Induced by Antineoplastic Agents;Pharmaceuticals;2024-08-20

3. Afatinib as first-line treatment for advanced lung squamous cell carcinoma harboring uncommon EGFR G719C and S768I co-mutation: A case report and literature review;Heliyon;2024-08

4. CACA guidelines for holistic integrative management of anticancer treatment - induced cutaneous adverse events;Holistic Integrative Oncology;2024-06-28

5. Safety and efficacy of pyrotinib for HER‑2‑positive breast cancer in the neoadjuvant setting: A systematic review and meta‑analysis;Oncology Letters;2024-03-04